AgeX Therapeutics (AGE) Sees Significant Growth in Short Interest

Share on StockTwits

AgeX Therapeutics (NYSE:AGE) saw a large growth in short interest in the month of January. As of January 31st, there was short interest totalling 1,108,419 shares, a growth of 1.4% from the January 15th total of 1,093,082 shares. Approximately 3.1% of the company’s shares are short sold. Based on an average daily trading volume, of 59,098 shares, the short-interest ratio is presently 18.8 days.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. BlackRock Inc. purchased a new position in shares of AgeX Therapeutics during the 4th quarter valued at $1,810,000. Defender Capital LLC. acquired a new position in shares of AgeX Therapeutics during the 4th quarter worth $1,379,000. Geode Capital Management LLC acquired a new stake in shares of AgeX Therapeutics during the 4th quarter valued at approximately $366,000. Northern Trust Corp purchased a new stake in AgeX Therapeutics in the 4th quarter worth about $293,000. Finally, Price Capital Management Inc. bought a new position in AgeX Therapeutics in the 4th quarter valued at $210,000. Institutional investors and hedge funds own 0.21% of the company’s stock.

AGE stock opened at $4.10 on Thursday. AgeX Therapeutics has a fifty-two week low of $1.13 and a fifty-two week high of $5.95.

COPYRIGHT VIOLATION WARNING: This piece was originally posted by Macon Daily and is the sole property of of Macon Daily. If you are reading this piece on another website, it was illegally copied and reposted in violation of US & international copyright laws. The legal version of this piece can be read at https://macondaily.com/2019/02/14/agex-therapeutics-age-sees-significant-growth-in-short-interest.html.

AgeX Therapeutics Company Profile

AgeX Therapeutics, Inc, a biotechnology company, focuses on the development and commercialization of therapeutics for age-related degenerative diseases in the United Stated. The company is developing AGEX-BAT1 and AGEX-VASC1, which are cell-based approaches in the preclinical stage of development to correct metabolic imbalances in aging; and to restore vascular support in ischemic tissues.

Featured Article: Cash Flow Analysis in Stock Selection

Receive News & Ratings for AgeX Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AgeX Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply